Clinical, pathological, immunological, and virological evidence suggests that simian varicella virus (SW) infection of primates is the counterpart ofvaricella-zoster virus infection of humans. To determine whether these two viruses share similrities in their properties during latency, we analyzed ganglia and brain of an African green monkey experimentally infected with SW for the presence of viral nucleic acid using the polymerase chain reaction technique. We detected SW DNA in dorsal root ganglia but not in brain of this monkey, which demonstrated no apparent clinical signs of SW infection. Ohr results suggest that SW becomes latent in monkey ganglia and that latency can develop in the absence of clinical varicella (chickenpox). These studies provide an animal model system to study varicella virus latency.
share similrities in their properties during latency, we analyzed ganglia and brain of an African green monkey experimentally infected with SW for the presence of viral nucleic acid using the polymerase chain reaction technique. We detected SW DNA in dorsal root ganglia but not in brain of this monkey, which demonstrated no apparent clinical signs of SW infection. Ohr results suggest that SW becomes latent in monkey ganglia and that latency can develop in the absence of clinical varicella (chickenpox). These studies provide an animal model system to study varicella virus latency.
Varicella-zoster virus (VZV) causes chickenpox (varicella)
in childhood, becomes latent in dorsal root ganglia, and reactivates decades later to produce shingles (zoster) in adults. The host range of VZV is restricted exclusively to humans,' so that no animal model has been developed to study VZV pathogenesis and latency. However, there have been various reports of spontaneous epizootic outbreaks of varicella in housed monkeys. Like human varicella, simian varicella frequently occurs in epidemics, has an incubation period of 1 or more weeks, and histologic examination of skin lesions reveals necrosis and hemorrhagic foci of epidermal cells containing intranuclear inclusions (1) . The causative agent of simian varicella is a member of the herpesvirus family, simian varicella virus (SVV), which is antigenically crossreactive with VZV (2, 3) . SVV also reactivates in monkeys to produce disseminated varicella (3) . If the'site of SVV latency is ganglionic as has been shown for human VZV (4, 5) , then studies of SVV pathogenesis and latency in primates would be relevant to human VZV infection. In the present study, we demonstrate the presence of latent SVV DNA in ganglia and the establishment of latent infection in a monkey which seroconverted after experimental infection with SVV but failed to develop clinical varicella. METHODS SW. The deltaherpesvirus (DHV) strain of SVV was originally isolated from a naturally infected patas monkey (Erythocebus patas) as described (6) and propagated in Vero cells, and a virus stock was prepared as described (7, 8) .
Virus Inoculation. A 6-year-old female African green monkey (Cercopithecus aethiops) was inoculated with SVV as described (8) . Briefly, 105 plaque-forming units of SVV in 1.5 ml was administered by intratracheal catheter into the upper bronchi, and 1.5 ml was injected subcutaneously over the abdomen. Two days after inoculation, the monkey was treated intramuscularly with a purine nucleoside, B722U (Burroughs Wellcome), at 150 mg/kg of body weight per day for 10 days. The monkey was examined daily for a varicelliform eruption. Blood was collected every few days for detection of viremia and on days 14 and 21 after inoculation for determination of antibody titer to SVV (9) . DNA Isolation. Total DNA was extracted from brain and from ganglia-two trigeminal, six thoracic, and four cervical ganglia-of the monkey. Tissues were thawed and homogenized (Dounce homogenizer) in 2 ml of0.010 M Tris HCI, pH 7.5/0.1 M NaCI/50 mM EDTA (TNE buffer) per0.5 cm2 oftissue at 40C and were digested with sodium dodecyl sulfate (0.5% final concentration) and proteinase K (200 gg/ml) for 1 -hr at 370C or overnight at room temperature. DNA was extracted three times with phenol, twice with phenol/chloroform, 1:1 (vol/vol), and three times with chloroform; was precipitated with ethanol; and was redissolved in 0.010 M Tris HCI, pH 8.0/0.001 M EDTA (TE buffer) (100 ILI per 0.5 cm2 of tissue). DNA was also extracted from BSC-1 cells, VZV-infected BSC-1 cells, and SVV-infected BSC-1 cells as described (10) . DNA concentrations were estimated by optical density at 260 nm, and final concentrations were adjusted to 1 tug/,uI.
Cloning and Sequencing of SW BamHI Fragment P Recombinant Clone. DNA isolated from purified SVV was digested with BamHI and ligated to a transcription vector (pGEM-4; Promega) that had been linearized with BamHI.
The ligation mixture was used to transform Escherichia coli strain HB101. A recombinant clone (p53) containing the 1-kilobase-pair (kbp) SVV BamHI P fragment was selected for sequencing by using [a-32P]dATP at a specific activity of >600 Ci/mmol (1 Ci = 37 GBq; ICN), SP6 promoter/primer, and the T7 DNA polymerase system (Promega) as described (11) . The products were separated on a 6% polyacrylamide sequencing gel and exposed for 16 hr to a Kodak X-Omat AR film.
Polymerase Chain Reaction (PCR The DNA fragments were transferred to nitrocellulose filters and hybridized to 32P-labeled riboprobes synthesized by using SP6 RNA polymerase and HindIll-linearized recombinant clone p53 containing the SVV BamH1 P (1000 bp) fragment in pGEM4. Filters were washed and exposed to Kodak X-Omat film for 16 hr. a 2-min annealing step at 450C, and an elongation step of3 min at 72°C with an automatic extension of the elongation step by 15 sec per cycle. The total number of cycles was 35. As a control, no DNA was included in one of the reaction tubes.
Detection of Virus-Specific Sequences in PCR-Amplified Products. Synthetic oligonucleotides representing a region internal to the amplified fragment were dissolved in sterile water to a final concentration of 0.1 ,ug/,lL, and an aliquot (20 ,ul) was used for end-labeling with [y-32PJATP (7000 Ci/ mmol; ICN) as described (11) . Three microliters of the 100-,ul PCR mixture containing SVV-infected cell DNA and 12 ,u1 from the others were used for analysis. Amplified DNA fragments were separated on a 2% agarose gel in 0.04 M Tris acetate/0.002 M EDTA, pH 8.0. DNA fragments in the agarose gel were transferred to Zeta-Probe (Bio-Rad) membranes, hybridized to 32P-end-labeled oligonucleotide probes, and detected by autoradiography per the manufacturer's instructions. The size of the amplified product was determined by comparison with standard molecular weight markers (123-bp ladder, Bethesda Research Laboratories).
RESULTS AND DISCUSSION A 6-year-old female African green monkey was inoculated with 105 plaque-forming units of SVV by the intratracheal and subcutaneous routes (12) . As part of a study designed to determine the efficacy of a new antiviral agent, the monkey was treated 2 days after inoculation with a purine nucleoside for 10 days. separated on a 6% polyacrylamide sequencing gel and exposed for 16 hr to Kodak X-Omat AR film. A portion of the gel containing the 123-bp region used for amplification by PCR is presented. The sequence of the 16-mer oligonucleotide primers 1 and 2 on the two opposite DNA strands chosen for PCR and the 15-mer internal region 3 chosen for detection of the amplified material are indicated.
plaque-forming units of SVV. Ten days after reinoculation with SVV, the anti-SVV antibody titer was 1: 2560. Again, no rash or sign of clinical disease was observed. Five months after primary infection, the monkey was sacrificed, and DNA was extracted from two trigeminal, four cervical, and six thoracic ganglia and from brain for PCR analysis.
A recombinant clone (p53) containing the 1.0-kilobase (kb) SVV DNA BamHI P fragment in pGEM-4 was used to synthesize 32P-labeled riboprobe which was hybridized to BamHI-digested DNA from SVV-infected, VZV-infected, and uninfected BSC-1 cells. The specificity of the SVV riboprobe was demonstrated by its hybridization to only DNA from SVV-infected BSC-1 cells, corresponding to the 1.0-kbp SVV DNA BamHI P fragment but not to DNA from VZV-infected or uninfected BSC-1 cells (Fig. 1) .
The sequence of a 123-bp region of the SVV insert in clone p53 was determined by using the T7 DNA polymerase sequencing system (Promega) in the presence of SP6 promotor/primer and [a-32PjdATP (Fig. 2) . Oligonucleotide primers Primers used for amplification of SVV sequences are described in Fig. 2 . No DNA was included as a control (lane No DNA). Aliquots (12 ,ul) of the reaction mixtures (100 ,ul) were separated on a 2% agarose gel, transferred to a Zeta-Probe membrane and hybridized to a 32P-end-labeled oligonucleotide representing sequences internal to the amplified product (Fig. 2) . The size of the amplified products was determined by comparison with standard molecular weight markers (123-bp ladder). 4 . Detection of monkey ,B-globin sequences in DNA from monkey brain and trigeminal, thoracic, and cervical ganglia. The monkey f-globin sequences (83 bp) were amplified and detected as described in Fig. 3 . The sequences of the monkey 9-globin primers used for amplification were 5'-AGCTCGCTTTCTTGCTGTCC-3' and 5'-GCCCTTCATAATATCCCCCA-3', and that used for detection was 5'-TTCCCAAAGTCCAAC-3' (13) . No DNA was included as a control (lane No DNA).
detect the amplification products. The 123-bp SVV DNA fragment was amplified in preparations from trigeminal, cervical, and thoracic ganglia but not from brain (Fig. 3 ). An additional control was provided by the presence of an amplifiable 83-bp monkey P-globin DNA fragment in DNA from all monkey tissues (Fig. 4) .
These results indicate that the most probable site of SVV latency in primates is dorsal root ganglia. The detection of SVV DNA by PCR in multiple ganglia but not in brain parallels the detection of latent VZV in human ganglia from multiple levels of the neuraxis (5). Thus, both SVV and VZV appear to establish latency in multiple ganglia after primary infection. Moreover, SVV can establish latency in multiple ganglia without the development of varicella. Cases of subclinical human varicella infection (the presence of antibody to VZV without a history ofchickenpox) have been documented (14) ; whether VZV is latent in such individuals has not been studied. In conclusion, SVV infection in primates provides an appropriate animal model system to study varicella latency, an issue of major importance for the entire human population.
